Document Detail

Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridemic patients with a history of thrombosis.
MedLine Citation:
PMID:  1788834     Owner:  NLM     Status:  MEDLINE    
Impaired fibrinolysis due to high plasminogen activator inhibitor levels is present in patients with a variety of thrombotic diseases. Plasminogen activator inhibitor levels correlate with triglyceride levels and are elevated in patients with hypertriglyceridemia. Treatment of asymptomatic hypertriglyceridemic patients with diet or medication results in improvement of fibrinolytic parameters. To determine if similar improvements in fibrinolysis occur during treatment of hypertriglyceridemia in patients with a history of venous thrombosis and impaired fibrinolysis due to high plasminogen activator inhibitor levels, 5 patients were given gemfibrozil. Triglyceride levels and fibrinolytic response to venous occlusion were determined before and after 30 days of treatment. Gemfibrozil therapy resulted in a predictable decrease in triglyceride levels in all patients, a reduction that was statistically significant (p = 0.04). There was no significant change in fibrinolytic variables during gemfibrozil therapy. Independent factors appear to control the plasminogen activator inhibitor and triglyceride levels in patients with a history of venous thrombosis.
W D Haire
Related Documents :
11735104 - Recombinant factor viia (novoseven) restores deficient coagulation: experience from an ...
19641694 - Measurement of von willebrand factor as the marker of endothelial dysfunction in vascul...
16523414 - Biochemical markers of endothelial activation in primary hyperparathyroidism.
9894744 - Tissue factor and tissue factor pathway inhibitor in hemodialysis patients.
23714334 - Renal function and short-term outcome in stable outpatients with coronary, cerebrovascu...
620214 - Scleritis and associated disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Thrombosis research     Volume:  64     ISSN:  0049-3848     ISO Abbreviation:  Thromb. Res.     Publication Date:  1991 Nov 
Date Detail:
Created Date:  1992-03-20     Completed Date:  1992-03-20     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0326377     Medline TA:  Thromb Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  493-501     Citation Subset:  IM    
Department of Internal Medicine, University of Nebraska Medical Center, Omaha.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cholesterol / blood
Fibrinolysis / drug effects
Gemfibrozil / pharmacology*,  therapeutic use
Hypertriglyceridemia / blood,  complications,  drug therapy*
Plasminogen Inactivators / analysis*
Thrombophlebitis / complications*
Tissue Plasminogen Activator / analysis
Triglycerides / blood*
Reg. No./Substance:
0/Plasminogen Inactivators; 0/Triglycerides; 25812-30-0/Gemfibrozil; 57-88-5/Cholesterol; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Circadian variations of platelet aggregability and fibrinolytic activity in patients with ischemic s...
Next Document:  Temperature-dependence of LDL binding and activation of human platelets.